What Happened?
Cambridge, MA-based Voyager-Therapeutics Appointed Peter Pfreundschuh as Chief Financial Officer
About the Company
Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson`s disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich`s ataxia, Huntington`s disease, Alzheimer`s Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data.
About the Person
Peter Pfreundschuh is Chief Financial Officer at Voyager Therapeutics. Previously, Peter held various senior HR leadership roles in the industry.
Info Source
News
Short Profile